O6-methylguanine-DNA methyltransferase promoter methylation and isocitrate dehydrogenase mutation as prognostic factors in a cohort of Saudi patients with glioblastoma
BACKGROUND: Treatment of glioblastoma (GB), the most common malignant primary brain tumor in adults, can include alkylating chemo-therapeutic agents. Two molecular biomarkers of treatment response are MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation and IDH (isocitrate dehydrogenas...
Main Authors: | Ali H. Alassiri, Ali Alkhaibary, Saud Al-Sarheed, Fahd Alsufani, Mohammed Alharbi, Ahmed Alkhani, Ahmed Aloraidi |
---|---|
Format: | Article |
Language: | English |
Published: |
King Faisal Specialist Hospital and Research Centre
2019-12-01
|
Series: | Annals of Saudi Medicine |
Online Access: | https://www.annsaudimed.net/doi/full/10.5144/0256-4947.2019.410 |
Similar Items
-
Ki-67 labeling index in glioblastoma; does it really matter?
by: Ali Alkhaibary, et al.
Published: (2019-06-01) -
Isocitrate Dehydrogenase-1 Mutations as Prognostic Biomarker in Glioblastoma Multiforme Patients in West Bohemia
by: J. Polivka, et al.
Published: (2014-01-01) -
Isocitrate dehydrogenase
by: Illingworth, J. A.
Published: (1970) -
Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma
by: Sabrina P. Koh, et al.
Published: (2017-05-01) -
Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
by: Sejin Oh, et al.
Published: (2020-07-01)